Phase I/IIa Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Mise à jour : Il y a 4 ans
Référence : NCT01367444

Femme et Homme

Extrait

Primary Objective: To assess the safety and tolerability of ascending doses of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To evaluate for possible biological activity of SAR422459.


Critère d'inclusion

  • Stargardt Disease

Liens